04 June 2015
: Case report
A Patient with Urinary Tract Tuberculosis During Treatment with Etanercept
Unusual clinical course, Mistake in diagnosis, Diagnostic / therapeutic accidents, Unexpected drug reaction, Educational Purpose (only if useful for a systematic review or synthesis)
Shiho ShibataABCDEF, Eisuke ShonoBD, Emi NishimagiE, Ken YamauraEDOI: 10.12659/AJCR.893416
Am J Case Rep 2015; 16:341-346
Abstract
BACKGROUND: Tumor necrosis factor (TNF)-α inhibitors are widely used for rheumatoid arthritis (RA). However, there are several risks to use TNFα inhibitors. Given the properties of TNF-α inhibitors, prevention and early detection of tuberculosis (TB) are especially important. Even among TNF-α inhibitors, the risk of TB infection differs according to each drug. The incidence of TB is lowest with etanercept (ETN). We present a case of urinary tract TB during treatment with ETN.
CASE REPORT: A 58-year-old woman was receiving ETN for RA. Before starting ETN, isoniazid (INH) prophylaxis was started. RA was well controlled by ETN. However, 32 months after starting ETN, she noticed urinary frequency and a sensation of residual urine. The diagnosis was elusive, and it took 3 months until urinary tract TB was finally diagnosed. The TB resolved with antituberculosis medication, but RA disease activity flared up after ETN was discontinued. ETN was resumed with careful monitoring for TB recurrence. After resuming ETN, the RA was again well controlled, with no recurrence of TB.
CONCLUSIONS: Patients should be monitored for development of TB during ETN treatment, but ETN can be used safely with careful management.
Keywords: Anti-Inflammatory Agents, Non-Steroidal - therapeutic use, Antitubercular Agents - therapeutic use, Arthritis, Rheumatoid - drug therapy, Etanercept - therapeutic use, Follow-Up Studies, Tomography, X-Ray Computed, Tuberculosis, Urogenital - drug therapy
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.945747
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.945539
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.945795
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946588
Most Viewed Current Articles
21 Jun 2024 : Case report
88,518
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
50,005
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
25,154
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
22,640
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030